Fisher Asset Management Boosts Boston Scientific Holdings

Institutional investor increases stake in medical device company by nearly 10% in Q3 2025

Mar. 2, 2026 at 4:39pm

Got story updates? Submit your updates here. ›

Fisher Asset Management LLC, a major institutional investor, grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 9.8% in the third quarter of 2025, according to a recent 13F filing with the SEC. The firm now owns 8,461,025 shares of the medical equipment provider's stock, worth approximately $826 million.

Why it matters

This increase in ownership by a prominent institutional investor like Fisher Asset Management signals continued confidence in Boston Scientific's business outlook and growth potential. As a major medical device company, Boston Scientific's performance is closely watched by the investment community.

The details

According to the 13F filing, Fisher Asset Management purchased an additional 755,641 shares of Boston Scientific during the third quarter. This increased the firm's total stake in the company to approximately 0.57% of outstanding shares. The purchase comes as Boston Scientific has faced some headwinds, including a decline in its stock price over the past year.

  • Fisher Asset Management filed its 13F report for Q3 2025 on March 2, 2026.

The players

Fisher Asset Management LLC

A major institutional investment firm that manages over $200 billion in assets.

Boston Scientific Corporation

A global medical device company that develops and markets a wide range of products used in less-invasive medical procedures.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to have confidence in Boston Scientific's long-term growth potential despite the recent stock price volatility.”

— Ken Fisher, Founder and CIO, Fisher Asset Management

What’s next

Investors will be closely watching Boston Scientific's upcoming quarterly earnings report and any further updates on the company's product pipeline and strategic initiatives.

The takeaway

This increase in ownership by a prominent institutional investor like Fisher Asset Management underscores the continued appeal of Boston Scientific as a leading medical device company, even as it navigates some near-term headwinds.